| Reference |
|---|
Babl N, Hofbauer J, Matos C, Voll F, Menevse A, Rechenmacher M, et al. Low-density lipoprotein balances T cell metabolism and enhances response to anti-PD-1 blockade in a HCT116 spheroid model. Front Oncol. 2023;13:1107484 pubmed publisher |
Koutsakos M, Lee W, Reynaldi A, Tan H, Gare G, Kinsella P, et al. The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity. 2022;55:1316-1326.e4 pubmed publisher |
Li Y, Wang X, Jin J, Ma Z, Liu Y, Zhang X, et al. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. J Med Virol. 2022;94:3998-4004 pubmed publisher |
Balachandran H, Phetsouphanh C, Agapiou D, Adhikari A, Rodrigo C, Hammoud M, et al. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Rep. 2022;38:110345 pubmed publisher |
Georg P, Astaburuaga García R, Bonaguro L, Brumhard S, Michalick L, Lippert L, et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022;185:493-512.e25 pubmed publisher |
Smith A, Knochelmann H, Wyatt M, Rangel Rivera G, Rivera Reyes A, Dwyer C, et al. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022;10: pubmed publisher |
Vanshylla K, Fan C, Wunsch M, Poopalasingam N, Meijers M, Kreer C, et al. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host Microbe. 2022;30:69-82.e10 pubmed publisher |
Sulejmani O, Grunewald L, Andersch L, Schwiebert S, Klaus A, Winkler A, et al. Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. Cancers (Basel). 2021;13: pubmed publisher |
Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm A, et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021;39:1623-1642.e20 pubmed publisher |
Hu W, He M, Wang X, Sun Q, Kuang M. Specific CD8+ TCR Repertoire Recognizing Conserved Antigens of SARS-CoV-2 in Unexposed Population: A Prerequisite for Broad-Spectrum CD8+ T Cell Immunity. Vaccines (Basel). 2021;9: pubmed publisher |
Vitanza N, Johnson A, Wilson A, Brown C, Yokoyama J, K xfc nkele A, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27:1544-1552 pubmed publisher |
Harris M, Fuyal M, James J. Quantifying persistence in the T-cell signaling network using an optically controllable antigen receptor. Mol Syst Biol. 2021;17:e10091 pubmed publisher |
Wenthe J, Naseri S, Labani Motlagh A, Enblad G, Wikstrom K, Eriksson E, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021;70:2851-2865 pubmed publisher |
Buggert M, Vella L, Nguyen S, Wu V, Chen Z, Sekine T, et al. The Identity of Human Tissue-Emigrant CD8+ T Cells. Cell. 2020;183:1946-1961.e15 pubmed publisher |
Sekine T, Perez Potti A, Rivera Ballesteros O, Stralin K, Gorin J, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158-168.e14 pubmed publisher |
Freeman Z, Nirschl T, Hovelson D, Johnston R, Engelhardt J, Selby M, et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J Clin Invest. 2020;130:1405-1416 pubmed publisher |
Lamichhane R, Galvin H, Hannaway R, de la Harpe S, Munro F, Tyndall J, et al. Type I interferons are important co-stimulatory signals during T cell receptor mediated human MAIT cell activation. Eur J Immunol. 2020;50:178-191 pubmed publisher |
Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. 2019;19:895 pubmed publisher |
Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, et al. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep. 2019;9:2636 pubmed publisher |
Genoyer E, LOPEZ C. Defective Viral Genomes Alter How Sendai Virus Interacts with Cellular Trafficking Machinery, Leading to Heterogeneity in the Production of Viral Particles among Infected Cells. J Virol. 2019;93: pubmed publisher |
